Shareholder Alert: Ademi LLP investigates whether F-star Therapeutics, Inc. has obtained a Fair Price in its transaction with invoX

Published: Jun. 23, 2022 at 11:11 AM EDT

MILWAUKEE, June 23, 2022 /PRNewswire/ -- Ademi LLP is investigating F-star (NASDAQ:FSTX) for possible breaches of fiduciary duty and other violations of law in its transaction with invoX.

AdemiLogo (PRNewsfoto/Ademi LLP)
AdemiLogo (PRNewsfoto/Ademi LLP)(PRNewswire)

Click here to learn how to join the action: or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges F-star's financial outlook and prospects are excellent and yet F-star holders will receive only $7.12 per share. The acquisition values F-star at approximately $161 million. The transaction agreement unreasonably limits competing bids for F-star by imposing a significant penalty if F-star accepts a superior bid. F-star insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of F-star's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for F-star.

If you own F-star common stock and wish to obtain additional information, please contact Guri Ademi either at or toll-free: 866-264-3995, or

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.


Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:


The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.